NDAORALTABLET, EXTENDED RELEASE
Lifecycle
Pre-Launch
Clinical Trials
1
Data completeness
3/8 — Basic
TRILAFON (perphenazine) by Merck & Co. is clinical pharmacology pharmacokinetics following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. Approved for schizophrenia, psychotic disorders, bipolar disorder.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRILAFON (perphenazine) is an oral antipsychotic tablet indicated for schizophrenia, psychotic disorders, and bipolar disorder. It works through dopamine D2 and serotonin 5HT2A receptor antagonism, with hepatic metabolism via CYP2D6 showing genetic polymorphism affecting clearance in poor metabolizers. Peak plasma concentrations occur 1–3 hours post-dose with a 9–12 hour elimination half-life, reaching steady-state within 72 hours.
Growth
Pre-launch extended-release formulation with Merck backing offers growth opportunity; commercial team building and field force expansion likely underway.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics Following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. The plasma elimination half-life of perphenazine was independent of dose and ranged between 9 and 12 hours. In a study in…
Indications (3)
Investigational (3)
Worked on TRILAFON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.